Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation
Conti, R.M.; Rosenthal, M.B.
New England Journal of Medicine 374(8): 703-706
2016
ISSN/ISBN: 0028-4793 PMID: 26933845 DOI: 10.1056/nejmp1515068
Accession: 058537759
PDF emailed within 0-6 h: $19.90
Related References
Ognyanova, D.; Zentner, A.; Busse, R. 2011: Pharmaceutical reform 2010 in Germany : Striking a balance between innovation and affordability - La réforme de la politique du médicament en Allemagne : compromis entre innovation et l'accessibilité en terme de coût Eurohealth 17(1): 11-13Conrad, D.A.; Grembowski, D.; Hernandez, S.E.; Lau, B.; Marcus-Smith, M. 2014: Emerging lessons from regional and state innovation in value-based payment reform: balancing collaboration and disruptive innovation Milbank Quarterly 92(3): 568-623
Meisenberg, B. 2014: Balancing incentives and professionalism in health care payment reform Journal of Oncology Practice 10(6): 363-364
Pearson, C.; Schapiro, L.; Pearson, S.D. 2022: The next generation of rare disease drug policy: ensuring both innovation and affordability Journal of Comparative Effectiveness Research 11(14): 999-1010
Yin, W. 2008: Market incentives and pharmaceutical innovation Journal of Health Economics 27(4): 1060-1077
Lyles, A. 2006: Creating alternative incentives for pharmaceutical innovation Clinical Therapeutics 28(1): 126-128
Rai, A.K. 2001: The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era University of Illinois Law Review 1: 173-210
Doran, E.; Robertson, J. 2009: Australia's pharmaceutical cost sharing policy: reducing waste or affordability? Australian Health Review: a Publication of the Australian Hospital Association 33(2): 231-240
Kesselheim, A.S. 2010: Using market-exclusivity incentives to promote pharmaceutical innovation New England Journal of Medicine 363(19): 1855-1862
González, P.; Macho-Stadler, I.és.; Pérez-Castrillo, D. 2016: Private versus social incentives for pharmaceutical innovation Journal of Health Economics 50: 286-297
Karampli, E.; Souliotis, K.; Polyzos, N.; Kyriopoulos, J.; Chatzaki, E. 2014: Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece Hippokratia 18(2): 100-106
Walker, C.K. 2016: Neoliberalism and the reform of regulation policy in the Australian trucking sector: policy innovation or a repeat of known pitfalls? Policy Studies 37(1): 72-92
Zhang, L.; Wang, J. 2021: Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen Drug Development and Industrial Pharmacy 2021: 1-14
Petersen, L.; Sandhovel, A. 2001: Forestry policy reform and the role of incentives in Tanzania Forest Policy and Economics 2(1): 39-55
Mossinghoff, G.J. 1995: Health care reform and pharmaceutical innovation Drug Information Journal 29(4): 1077-1090